Q2-osavuosiraportti
73 päivää sitten‧37 min
Tarjoustasot
Oslo Børs
Määrä
Osto
17 021
Myynti
Määrä
144 166
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 | - | - | ||
| 29 384 | - | - | ||
| 2 137 | - | - | ||
| 13 478 | - | - | ||
| 5 000 | - | - |
Ylin
1,01VWAP
Alin
0,95VaihtoMäärä
0,7 765 157
VWAP
Ylin
1,01Alin
0,95VaihtoMäärä
0,7 765 157
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
Sijoittajakalenteri ei ole saatavilla | |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q2-osavuosiraportti | 28.8. | |
| 2024 Yhtiökokous | 5.6. | |
| 2024 Q4-osavuosiraportti | 10.4. | |
| 2024 Q2-osavuosiraportti | 29.8.2024 | |
| Merkintäoikeusanti | 20.6.2024 |
Datan lähde: Millistream, Quartr
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·1 päivä sittenCan someone explain how the stock can lose 40%, when there are only green numbers all the way?
·1 päivä sittenIt is based on the date, and shows percentage per week, month etc. You have to look from the day you bought. The graph is also not entirely correct, even if it tries to include parameters in the calculation. It becomes more incorrect the longer the time span. Becomes a bit misleading anyway. There's a reason why traders and economists create their own graphs and calculate based on this. I myself have never used calculations from Nordnet etc. They simplify all the way. Anyway, Circio is difficult to understand. We are waiting for the next news and hope and believe that they will manage it now. Much indicates that things are happening. Have mentioned it before here. Then the stock will possibly jump up, and maybe, or certainly, behave like a yo-yo. Or go through the roof, and then drop a bit too sharply for a period. Who knows. Biotech stocks are not logical, so calculating this is impossible. Good luck!- ·1 päivä sittenTekinvestor.. "Over the last year, Circio from November 2024 with Certest has established a total of 7 collaboration projects on the development, testing, and documentation of the technology. NeoRegen was the only one from before, but they demonstrably extended and expanded the collaboration in June 2025 after a long period of their own studies and testing of circVec. NeoRegen, Certest, 4Basebio, Lonza, Entos and an additional 2 confidential ones have conducted studies and testing internally, some of the studies have been parallel both at Circio and the partner for the sake of control. The development of circVec 3.2 and 4.0 as well as earlier versions has guaranteed been documented down to the smallest detail also in connection with IP work and applications. I would imagine there are “tons” of documentation on the circVec technology, construction, action, and effect in countless studies that Circio can put on the table in negotiations. A potential partner of a certain size will never trust any KOL report anyway, they have the competence and resources to themselves undertake the investigations and controls they deem necessary to enter into an agreement and commit financially in a partnership. When one also knows what internal competence Circio has - I can hardly understand that Circio should spend time and money on a KOL in the phase they are currently in. And finally, to repeat myself - Q4/25 was the first possible “valuepoint” Circio envisioned. Circio is only now there these days."
·1 päivä sitten · MuokattuTechnically, there is a buy signal building up now - there are some huge buys just below the line. https://www.tradingview.com/symbols/OSL-CRNA/technicals/
1 päivä sitten1 päivä sittenLook at the screenshot, does this stuck has only 1 owner now? 😁- ·1 päivä sittenWhat's happening, has Atlas stopped selling?·1 päivä sittenpossibly more will enter before Monday and the new week..
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Q2-osavuosiraportti
73 päivää sitten‧37 min
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·1 päivä sittenCan someone explain how the stock can lose 40%, when there are only green numbers all the way?·1 päivä sittenIt is based on the date, and shows percentage per week, month etc. You have to look from the day you bought. The graph is also not entirely correct, even if it tries to include parameters in the calculation. It becomes more incorrect the longer the time span. Becomes a bit misleading anyway. There's a reason why traders and economists create their own graphs and calculate based on this. I myself have never used calculations from Nordnet etc. They simplify all the way. Anyway, Circio is difficult to understand. We are waiting for the next news and hope and believe that they will manage it now. Much indicates that things are happening. Have mentioned it before here. Then the stock will possibly jump up, and maybe, or certainly, behave like a yo-yo. Or go through the roof, and then drop a bit too sharply for a period. Who knows. Biotech stocks are not logical, so calculating this is impossible. Good luck!
- ·1 päivä sittenTekinvestor.. "Over the last year, Circio from November 2024 with Certest has established a total of 7 collaboration projects on the development, testing, and documentation of the technology. NeoRegen was the only one from before, but they demonstrably extended and expanded the collaboration in June 2025 after a long period of their own studies and testing of circVec. NeoRegen, Certest, 4Basebio, Lonza, Entos and an additional 2 confidential ones have conducted studies and testing internally, some of the studies have been parallel both at Circio and the partner for the sake of control. The development of circVec 3.2 and 4.0 as well as earlier versions has guaranteed been documented down to the smallest detail also in connection with IP work and applications. I would imagine there are “tons” of documentation on the circVec technology, construction, action, and effect in countless studies that Circio can put on the table in negotiations. A potential partner of a certain size will never trust any KOL report anyway, they have the competence and resources to themselves undertake the investigations and controls they deem necessary to enter into an agreement and commit financially in a partnership. When one also knows what internal competence Circio has - I can hardly understand that Circio should spend time and money on a KOL in the phase they are currently in. And finally, to repeat myself - Q4/25 was the first possible “valuepoint” Circio envisioned. Circio is only now there these days."
- ·1 päivä sitten · MuokattuTechnically, there is a buy signal building up now - there are some huge buys just below the line. https://www.tradingview.com/symbols/OSL-CRNA/technicals/
- 1 päivä sitten1 päivä sittenLook at the screenshot, does this stuck has only 1 owner now? 😁
- ·1 päivä sittenWhat's happening, has Atlas stopped selling?·1 päivä sittenpossibly more will enter before Monday and the new week..
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
17 021
Myynti
Määrä
144 166
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 | - | - | ||
| 29 384 | - | - | ||
| 2 137 | - | - | ||
| 13 478 | - | - | ||
| 5 000 | - | - |
Ylin
1,01VWAP
Alin
0,95VaihtoMäärä
0,7 765 157
VWAP
Ylin
1,01Alin
0,95VaihtoMäärä
0,7 765 157
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
Sijoittajakalenteri ei ole saatavilla | |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q2-osavuosiraportti | 28.8. | |
| 2024 Yhtiökokous | 5.6. | |
| 2024 Q4-osavuosiraportti | 10.4. | |
| 2024 Q2-osavuosiraportti | 29.8.2024 | |
| Merkintäoikeusanti | 20.6.2024 |
Datan lähde: Millistream, Quartr
Q2-osavuosiraportti
73 päivää sitten‧37 min
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
Sijoittajakalenteri ei ole saatavilla | |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q2-osavuosiraportti | 28.8. | |
| 2024 Yhtiökokous | 5.6. | |
| 2024 Q4-osavuosiraportti | 10.4. | |
| 2024 Q2-osavuosiraportti | 29.8.2024 | |
| Merkintäoikeusanti | 20.6.2024 |
Datan lähde: Millistream, Quartr
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·1 päivä sittenCan someone explain how the stock can lose 40%, when there are only green numbers all the way?·1 päivä sittenIt is based on the date, and shows percentage per week, month etc. You have to look from the day you bought. The graph is also not entirely correct, even if it tries to include parameters in the calculation. It becomes more incorrect the longer the time span. Becomes a bit misleading anyway. There's a reason why traders and economists create their own graphs and calculate based on this. I myself have never used calculations from Nordnet etc. They simplify all the way. Anyway, Circio is difficult to understand. We are waiting for the next news and hope and believe that they will manage it now. Much indicates that things are happening. Have mentioned it before here. Then the stock will possibly jump up, and maybe, or certainly, behave like a yo-yo. Or go through the roof, and then drop a bit too sharply for a period. Who knows. Biotech stocks are not logical, so calculating this is impossible. Good luck!
- ·1 päivä sittenTekinvestor.. "Over the last year, Circio from November 2024 with Certest has established a total of 7 collaboration projects on the development, testing, and documentation of the technology. NeoRegen was the only one from before, but they demonstrably extended and expanded the collaboration in June 2025 after a long period of their own studies and testing of circVec. NeoRegen, Certest, 4Basebio, Lonza, Entos and an additional 2 confidential ones have conducted studies and testing internally, some of the studies have been parallel both at Circio and the partner for the sake of control. The development of circVec 3.2 and 4.0 as well as earlier versions has guaranteed been documented down to the smallest detail also in connection with IP work and applications. I would imagine there are “tons” of documentation on the circVec technology, construction, action, and effect in countless studies that Circio can put on the table in negotiations. A potential partner of a certain size will never trust any KOL report anyway, they have the competence and resources to themselves undertake the investigations and controls they deem necessary to enter into an agreement and commit financially in a partnership. When one also knows what internal competence Circio has - I can hardly understand that Circio should spend time and money on a KOL in the phase they are currently in. And finally, to repeat myself - Q4/25 was the first possible “valuepoint” Circio envisioned. Circio is only now there these days."
- ·1 päivä sitten · MuokattuTechnically, there is a buy signal building up now - there are some huge buys just below the line. https://www.tradingview.com/symbols/OSL-CRNA/technicals/
- 1 päivä sitten1 päivä sittenLook at the screenshot, does this stuck has only 1 owner now? 😁
- ·1 päivä sittenWhat's happening, has Atlas stopped selling?·1 päivä sittenpossibly more will enter before Monday and the new week..
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
17 021
Myynti
Määrä
144 166
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 | - | - | ||
| 29 384 | - | - | ||
| 2 137 | - | - | ||
| 13 478 | - | - | ||
| 5 000 | - | - |
Ylin
1,01VWAP
Alin
0,95VaihtoMäärä
0,7 765 157
VWAP
Ylin
1,01Alin
0,95VaihtoMäärä
0,7 765 157
Välittäjätilasto
Dataa ei löytynyt